Antihyperglycaemic treatment patterns, observed glycaemic control and determinants of treatment change among patients with type 2 diabetes in the United Kingdom primary care: a retrospective cohort study

Table 1 Baseline patient characterization by main OAD at index date

	OAD at index date				Total*
	Mono: metformin	Mono: gliclazide	Mono: glimepiride	Metformin & gliclazide	Total*
Number of patients (n)	55,522	5,132	417	927	63,060
Mean age at index date (years)	60.97	67.13	66.84	59.04	61.50
Gender (% male)	56.51	57.50	57.31	61.27	56.70
Median time from Dx diabetes to OAD initiation** (months)	11.9	10.5	12.17	0.77	11.63
Mean HbA1c in last 6 months (mmol/mol)	70.12	78.30	76.73	97.42	71.05
Median HbA1c in last 6 months (mmol/mol)	64.00	70.00	67.00	99.00	65.00
% of patients with HbA1c >59 mmol/mol	63.10	70.40	65.60	82.10	63.90
Median BMI	31.60	26.60	26.50	30.90	31.20
Coronary Heart Disease (%)	16.33	22.35	21.58	13.59	16.84
Cerebrovascular D’ (%)	6.04	10.76	11.75	6.47	6.48
Nephropathy (%)	0.56	1.73	0.72	0.11	0.66
Retinopathy (%)	4.47	4.35	7.43	1.83	4.45
Neuropathy (%)	0.64	0.80	0.96	0.22	0.65
CHF (%)	2.78	9.08	7.67	3.67	3.38
Hypertension*** (%)	54.74	51.79	50.84	43.04	54.23

*All patients included in the study hence summing to more than the four specific OAD groups.
**Duration is calculated from the time from first diagnostic code of diabetes if it occurs prior to initiation of OAD (some codes occurred later than OAD).
***Hypertension defined at any time prior to initiation of OAD therapy.

ISSN: 1472-6823